Company news: Dendreon and CPPIB Credit Investments

Share this article:

Dendreon agreed to sell its royalty interest in Victrelis (boceprevir) for $125 million in cash, the company said. The firm did not disclose the exact royalty rate. The royalty interest was acquired by CPPIB Credit Investments, a wholly-owned subsidiary of CPP Investment Board, and the transaction is expected to close this month. ISI Group analyst Mark Schoenebaum estimated peak global Victrelis sales of $970.5 million in 2014. All-oral therapies, such as Gilead/Pharmassset's PSI-7977 could reach market in 2015 and are expected to impact currently marketed HCV drugs like Merck/Roche's Victrelis.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.